Our results confirm the results of a previous study by Uckun et al., who reported a delay in tumor progression in the MMTV/Neu transgenic mouse model of HER2-positive breast cancer after LFM-A13 administration [18]. The gene discussed is ERBB2; the disease is neoplasm.